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Background: Several single-nucleotide polymorphisms (SNPs) are known to increase the risk of Hashimoto’s
thyroiditis (HT); such SNPs reside in thyroid-specific genes or in genes related to autoimmunity, inflammation,
and/or cellular defense to stress. The transcription factor Nrf2, encoded by NFE2L2, is a master regulator of the
cellular antioxidant response. This study aimed to evaluate the impact of genetic variation in NFE2L2 on the
risk of developing HT.
Methods: In a case–control candidate gene association study, functional SNPs in the NFE2L2 promoter
(rs35652124, rs6706649, and rs6721961) were examined either as independent risk factors or in combination
with a previously characterized HT risk allele (rs28665122) in the gene SELENOS, encoding selenoprotein S
(SelS). A total of 997 individuals from the north of Portugal (Porto) were enrolled, comprising 481 HT patients
and 516 unrelated healthy controls. SELENOS and NFE2L2 SNPs were genotyped using TaqMan assays and
Sanger sequencing, respectively. Odds ratios (ORs) were calculated using logistic regression, with adjustment
for sex and age. Expression of SelS was analyzed by immunohistochemistry in thyroid tissue from HT patients
and control subjects. Molecular interactions between the Nrf2 and SelS pathways were investigated in thyroid
tissues from mice and in rat PCCL3 thyroid follicular cells.
Results: When all three NFE2L2 SNPs were considered together, the presence of one or more minor alleles was
associated with a near-significant increased risk (OR=1.43,p=0.072). Among subjects harboring only majorNFE2L2
alleles, there was no increased HT risk associated with heterozygosity or homozygosity for the SELENOSminor allele.
Conversely, in subjects heterozygous or homozygous for the SELENOS risk allele, the presence of anNFE2L2minor
allele significantly increased HT risk by 2.8-fold ( p= 0.003). Immunohistochemistry showed reduced expression of
SelS in thyroid follicular cells of HT patients. In Nrf2 knockout mice, there was reduced expression of SelS in thyroid
follicular cells; conversely, in PCCL3 cells, reducing SelS expression caused reduced activity of Nrf2 signaling.
Conclusions: TheNFE2L2 promoter genotype interacts with the SELENOS promoter genotype to modulate the risk
of HT in a Portuguese population. This interaction may be due to a bidirectional positive feedback between the Nrf2
and SelS pathways.
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Introduction
Hashimoto’s thyroiditis (HT) is a chronic autoimmunedisease with an annual incidence of 0.3–1.5/1000 and a
prevalence of up to 10% in the general population (1,2). It is
characterized by thyroid inflammation due to expansion of
thyroid antigen-specific lymphocytes that infiltrate the gland
and production of thyroid autoantibodies, leading to gradual
destruction of the thyroid parenchyma and often subsequent
hypothyroidism (3). HT is a multifactorial disorder whose
pathogenesis involves genetic and environmental predis-
posing factors (1,3–5). Twin studies estimate its heritability
at 70% (4), and several single-nucleotide polymorphisms
(SNPs) are known to increase the risk of HT. Such SNPs
reside either in thyroid-specific genes (e.g., TSHR and TG)
(6,7) or in genes related to autoimmunity, inflammation, and/
or cellular mechanisms of defense to stress (e.g., IL-1b, IL-6,
and TNF) (8,9).
We have previously identified one such HT susceptibility
gene, SELENOS, which encodes a member of the seleno-
protein family, selenoprotein S (SelS) (10). SELENOS is
expressed in multiple tissues, including thyroid follicular
cells, and the protein it encodes is involved in cellular stress
responses as a mediator of endoplasmic reticulum (ER)-
associated protein degradation (ERAD) of misfolded proteins
(11), as well as in immune and inflammatory processes (12).
We previously showed that a functional SNP in the SELENOS
promoter (rs28665122, -105G/A) is associated with increased
risk of HT (10). Specifically, heterozygosity or homozygosity
for the minor allele (GA or AA, respectively) was significantly
more frequent in HT patients than in healthy controls, in-
creasing the risk of HT by more than twofold (10). In lu-
ciferase reporter gene assays, the allele A shows reduced
promoter transcriptional activity (12), which suggests that
reduced SELENOS transcription may influence the proin-
flammatory cytokine profiles observed in thyroid autoim-
munity and/or the proteostatic responses of thyroid follicular
cells, thereby predisposing to HT.
We hypothesized that additional risk factors for HT might
reside in cellular systems that regulate or cross talk to sele-
noproteins and mediate complementary and/or overlapping
cellular stress responses. One such candidate is NFE2L2,
which encodes the nuclear factor-erythroid 2-related tran-
scription factor 2 (NFE2L2 or Nrf2), a member of the
cap’n’collar leucine zipper family (13). Nrf2 is known to
regulate the basal and inducible expression of a battery of cell
protective genes that encode antioxidant and detoxification
enzymes, proteasome subunits, and other proteostasis medi-
ators (14). In the absence of oxidative stress, Nrf2 binds to its
cytoplasmic inhibitor Kelch-like ECH-associated protein 1
(Keap1), which targets Nrf2 for polyubiquitination and pro-
teasomal degradation (13,15). Keap1 also functions as a
sensor of oxidants and electrophiles, which react with its
redox-sensitive cysteines (16,17). Oxidative stressors abolish
the inhibition of Nrf2 by Keap1; Nrf2 then accumulates in the
nucleus where it transcriptionally activates protective genes
through antioxidant response elements (AREs) in their reg-
ulatory sequences (13). Studies in different tissues have
shown that Nrf2 regulates hundreds of genes, including
several selenoproteins (13,14). In addition, multiple lines of
evidence indicate that the selenoprotein system and the Nrf2
system can compensate for each other in antioxidant stress
responses, such that the simultaneous disruption of both
systems is particularly deleterious to proteostasis (18–23).
The human NFE2L2 gene maps to chromosome 2q31 and
consists of 5 exons and 4 introns. Three functional SNPs have
been identified in the NFE2L2 promoter (24): rs35652124,
-214A>G; rs6706649, -212G>A; and rs6721961, -178A>C—
nomenclature according to a study (25). Each of these SNPs has
been found to affect the expression level of Nrf2, with the
minor alleles associated with a lower promoter activity (26,27).
These polymorphisms have been associated with several dis-
eases related to oxidative stress (25), such as acute lung injury
(26), asthma (28), Parkinson’s disease (29), Alzheimer’s dis-
ease (30), and others, including autoimmune diseases such as
systemic lupus erythematosus (31) and vitiligo (32).
Autoimmune thyroid disease has also been associated with
systemic oxidative stress (33,34); however, the potential role
of NFE2L2 SNPs in susceptibility to autoimmune thyroid
disease has not been addressed. Interestingly, Nrf2 knockout
(KO) mice are known to develop an age-related multiorgan
autoimmune syndrome (35–37), but it has not been reported
whether the thyroid gland is also affected. Recently, we showed
that Nrf2 positively controls thyroglobulin expression while
limiting its iodination in the thyroid of mice (38). We also
showed that Nrf2 positively controls the thyroidal expression of
antioxidant genes, including those encoding the selenoproteins
glutathione peroxidase 2 (Gpx2) and thioredoxin reductase 1
(Txnrd1) (38), which are both known to have important roles in
follicular cell homeostasis (39,40). However, the involvement
of Nrf2 in autoimmune thyroid disease has not been investi-
gated. For these reasons, we investigated whether the known
functional NFE2L2 promoter SNPs, either individually or in
combination with each other and/or with the known SELE-
NOS promoter functional SNP, modulate the risk of HT.
Materials and Methods
Study subjects
Associations between the three NFE2L2 promoter SNPs
and the SELENOS promoter SNP and the risk of HT were
assessed in a case–control study using cohorts that have been
previously described in detail (10). Briefly, a total of 997
subjects were enrolled; these included 481 genetically unre-
lated HT patients (441 females and 40 males; mean age 55.3
years; range 30–62 years) enrolled at the Department of
Endocrinology of Hospital of S. Joa˜o (Porto, Portugal). The
control group comprised 516 subjects (479 females and 37
males; mean age 46.3 years; range 18–83 years) recruited
among unrelated healthy blood donors. Patients were en-
rolled between 2007 and 2013; diagnosis was made based on
the presence of positive serum autoantibodies against thyroid
peroxidase and/or thyroglobulin and negative serum auto-
antibodies against the thyrotropin (TSH) receptor, according
to methods applied before or after March 2009 in the De-
partment of Clinical Pathology of Hospital of S. Joa˜o, in
conjunction with a typical ultrasound pattern of the thyroid
parenchyma (i.e., diffuse hypoechogenicity and heterogene-
ity). Subjects with a reported history of thyroid cancer and/or
prior thyroid surgery were excluded. The biochemical char-
acteristics of the patient cohort have been reported previ-
ously (10); all patients were treated with levothyroxine
for HT-related hypothyroidism. The control group, healthy
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blood donors without apparent infectious and/or chronic
disorders, consisted of permanent residents in the area ser-
viced by the Hospital of S. Joa˜o, selected during the assembly
of the EpiPorto cohort (41). The study was authorized by the
Hospital of S. Joa˜o Ethics Committee and informed consent
was obtained from all participants.
Formalin-fixed paraffin-embedded thyroid tissue samples
from control subjects (n = 10) or patients with HT (n = 8),
collected during thyroidectomy performed for other indica-
tions (notably benign goiter), were obtained from the archives
of Lausanne University Hospital, with authorization from
the Ethics Committee of the Canton of Vaud (study no.
2017-00944).
Genotyping
Genomic DNA from patients and controls was iso-
lated from blood using standard proteinase K digestion
with phenol/chloroform extraction. For the NFE2L2 SNPs
rs35652124, rs56706649, and rs6721961, polymerase chain
reaction (PCR) amplifications were performed using forward
primer 5¢-CTGCGCTTTGGTGGGAAG-3¢ and reverse pri-
mer 5¢-TGGAGTTGCAGAACCTTGC-3¢. Briefly, PCR
amplifications were performed in 25 lL volume reactions
containing 100 ng genomic DNA, 100 lM of each dNTP,
0.1 lg of each primer, 1 ·GoTaq Flexi Buffer (Promega,
Madison, WI), 2.5 mM MgCl2, and 0.15 U of GoTaq G2 Flexi
DNA Polymerase (Promega). Reaction mixtures were sub-
mitted to 35 amplification cycles preceded by a Taq activa-
tion step at 95 C for 5 minutes; each cycle comprised a
denaturation step at 95 C for 30 seconds, annealing at 59 C
for 30 seconds, and extension at 72 C for 45 seconds fol-
lowed by a final extension at 72 C for 5 minutes. PCR
products were then purified by enzymatic digestion with
exonuclease I (Thermo Fisher Scientific, Waltham, MA) and
shrimp alkaline phosphatase (Thermo Fisher Scientific) and
sequenced using the BigDye Terminator v3.1 Kit (Applied
Biosystems, Foster City, CA) and an ABI Prism 3100 Genetic
Analyzer (Perkin-Elmer, Waltham, MA). In a randomly se-
lected 10% of the samples, PCR and sequencing were per-
formed twice to verify the reproducibility of the technique.
The number of subjects successfully genotyped for each
NFE2L2 SNP differed slightly according to the success of the
respective sequencing reaction assay. Genotyping of SELENOS
rs28665122 in the same subjects had been performed previously
using TaqMan assays (10).
Mice
C57BL/6J Nrf2+/- mice, originally developed by Prof. M.
Yamamoto (42), were obtained from RIKEN BRC (Tsukuba,
Japan). Mice were housed in the animal facility of the Uni-
versity of Patras Medical School in temperature-, light-, and
humidity-controlled rooms with a 12-hour light/dark cycle.
All animal procedures were approved by the local institu-
tional review board and were in accordance with the Euro-
pean Commission Directive 86/609/EEC. Generation of
wild-type (WT) and KO (Nrf2-KO) mice and tissue collec-
tion has been previously described (38).
Cell culture
PCCL3 cells, a clonal rat thyroid cell line (43), were cultured
in Coon’s modified Ham’s F-12 under conditions described
previously (38). Culture media and supplements were all from
Sigma-Aldrich (St-Louis, MO). Generation of PCCL3
Nrf2-KO and PCCL3 Keap1-KO cells using CRISPR/Cas9
technology has been previously described (38).
Cell viability assay
The CellTiter-Glo Luminescent Cell Viability Assay Kit
(Promega) was used according to the manufacturer’s protocol
to determine the number of viable cells in culture based on
the quantification of adenosine triphosphate. Briefly, cells
were lysed by adding 100 lL CellTiter-Glo reagent to each
well and the luminescence intensity was measured 10 min-
utes later on a NOVOstar multimode reader (BMG Labtech,
Ortenberg, Germany). Results were expressed as fold change
over the untreated control sample.
RNA isolation and real-time PCR
Total RNA isolation and real-time PCR (RT-PCR) from
mouse tissues and from cell lines were performed as previ-
ously described (38). Melt curve analysis was used to confirm
gene-specific amplification. Relative gene expression was
calculated by the comparative cycle threshold method using
PPIA as reference gene for thyroid and liver tissues and
RPL19 for PCCL3 cells. Primers for RT-PCRs are shown in
Supplementary Tables S1–S3.
Protein isolation, Western immunoblotting,
and immunohistochemistry
Total protein isolation and Western blots were performed
as previously described (38). The following primary anti-
bodies were used: anti-SelS (HPA010025, 1:3000; Sigma-
Aldrich), produced in rabbit, a Prestige Antibody, developed
and validated by the Human Protein Atlas (HPA) project;
anti-vinculin (SAB4200080, 1:5000; Sigma-Aldrich); and
anti-b-actin (#4967, 1:5000; Cell Signaling, Danvers, MA).
Secondary antibodies were anti-mouse HRP (#7076) and
anti-rabbit HRP (#7074) both from Cell Signaling (1:5000).
Immunohistochemistry was performed on slices from
formalin-fixed paraffin-embedded human or mouse thyroid
tissues as previously described (38,44) using the aforemen-
tioned primary antibody against SelS. Specific binding was
detected with the Envision Kit (Dako), and the color reaction
was visualized with 3,3¢-diaminobenzidine. For negative con-
trols, blocking solution was added instead of a primary antibody.
RNA interference
Silencing of SelS was performed using the DsiRNA
TriFECTa Kit (cat. no. 1 rn.Ri.Vimp.13; Integrated DNA
Technologies, Coralville, IA). This kit contains three different
small interfering RNAs (siRNAs) targeting the rat SelS RNA
transcript and a universal negative control siRNA that was
tested in parallel. Initially, each individual siRNA was tested in
PCCL3 cells using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, CA) at a final siRNA concentration of 20 nM. Next,
conditions for siRNA transfection were optimized by pooling
together the three different individual siRNAs at a final con-
centration of 6.6 nM each. Compound treatments were per-
formed 24 hours later and cells were collected 48–72 hours
after the siRNA transfections.
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Cell treatments
Unless otherwise stated, all chemicals were from
Sigma-Aldrich. The following compounds were used for
cell treatments: sulforaphane (SLF, R-1-isothiocyanato-4-
methylsulfinylbutane) was used as Nrf2 activator (45).
Oxidative stress conditions were induced using menadione
(2-methyl-1,4-naphthoquinone, vitamin K3), a redox-
cycling agent widely used in the literature to induce oxi-
dative damage (46). In preliminary experiments, various
ranges of concentrations and treatment times were tested
to identify conditions where the viability of WT cells re-
mained unaffected. Finally, an 8-hour treatment at a con-
centration of 20 nM was used in all experiments. To
induce ER stress, cells were treated with the protein gly-
cosylation inhibitor tunicamycin A (TN) at a concentration
of 0.5 mg/mL (47).
Promoter analysis, cell transfections,
and reporter assays
The promoter sequence of the human SELENOS gene was
downloaded from the EPDnew database (promoter ID:
VIMP_1, https://epd.epfl.ch//index.php). The JASPAR core
database (http://jaspar.genereg.net) (48) was used to locate
potential Nrf2 binding sites (ARE weight matrix, MA0150.2;
relative score 0.80) in a 3 kb region upstream of the transla-
tion start site of SELENOS. Human genomic DNA was used
as a template to amplify different lengths of the SELENOS
promoter by PCR using Kapa HiFi HotStart high-fidelity
DNA polymerase (Kapa Biosystems, Wilmington, MA).
Primers (Supplementary Tables S1–S3) were designed to
contain KpnI and BglII restriction sites to facilitate the
cloning of PCR products into the PGL3 basic luciferase
vector (Promega). Three promoter reporter constructs of
different lengths were created, hereafter referred to as P1
(-481 to +54 bp), P2 (-1017 to +54 bp), and P3 (-2168 to
+54 bp). Promoter P1 does not harbor any potential Nrf2
binding sites, P2 harbors one potential ARE (ARE1, -863 to
-849), and P3 harbors ARE1 and another potential ARE
(ARE2, -2062 to -2051).
Transient transfections of cells with the different promoter
reporter constructs were performed in 48-well plates cultured
in complete medium using a 1:2 ratio of DNA and jetPRIME
transfection reagent, respectively. In all transfections, the
pEGFP-N1 plasmid (Clontech, Mountain View, CA) was
included for monitoring transfection efficiency and normal-
izing luciferase activities, as previously described (49).
Treatment of cells with SLF (5 lM) or TN (0.5 lg/mL) or
vehicle (DMSO or dimethylsulfoxide) was performed
24 hours after transfection. Cells were lysed 48 hours after
transfection using the passive lysis buffer (Promega), and
green fluorescent protein (GFP) fluorescence was mea-
sured using a NOVOstar multimode reader with an excita-
tion wavelength of 480 nm and an emission wavelength of
520 nm. The GFP fluorescence background of untransfected
cells was used for blank measurements. After measuring GFP
fluorescence, luciferase activities were measured in the same
plates using the luciferase assay system (Promega) according
to the manufacturer’s protocol. Luciferase activities were
normalized to the respective GFP fluorescence measure-
ments, and relative luciferase activities were expressed as
fold change over control.
Statistics
For the genetic studies, statistical analyses were per-
formed using SPSS v.25.0 (IBM, Armonk, NY). The Hardy–
Weinberg equilibrium was evaluated using a chi-square test.
Comparison of genotype frequencies between HT patients
and controls was performed using unconditional logistic re-
gression. Odds ratios (ORs) with the respective 95% confi-
dence intervals (CIs) for association of the SELENOS and
NFE2L2 polymorphisms with HT were calculated for the
genotypic and dominant models of inheritance with adjust-
ment for sex and age. Controlling for the effects of multiple
testing was performed by the false discovery rate (FDR)
method (50).
For ordinal data (staining intensity in control vs. Ha-
shimoto’s samples), the Kruskal–Wallis test was used in
GraphPad Prism 8 (GraphPad Software, La Jolla, CA), which
was also used to prepare all graphs. For data calculated as
normalized ratios [messenger RNA (mRNA), protein, and
luciferase quantifications], the BootstRatio application was
used; this tool is based on bootstrapping and resampling
methods without any assumption on the underlying proba-
bility distribution for the data analyzed (51). Whenever the
same data were used to test multiple hypotheses, a Bonferroni
correction was applied as appropriate.
Results
Distribution of NFE2L2 promoter SNP genotypes
and haplotypes and HT risk
In the control group, the genotype frequencies for all three
NFE2L2 SNPs (as well as for SELENOS rs28665122) did not
deviate significantly from those expected under Hardy–
Weinberg equilibrium (all p> 0.05). The impact of each
NFE2L2 SNP was first examined individually and indepen-
dently of the SELENOS SNP. These analyses included subjects
successfully genotyped for each NFE2L2 SNP: rs35652124
(403 patients and 514 controls); rs6706649 (403 patients and
543 controls); and rs6721961 (403 patients and 555 controls).
On an individual basis, none of the NFE2L2 SNP genotypes
showed a significant association with the risk of HT (all
p> 0.05; Table 1). A per allele analysis confirmed the absence
of statistically significant associations for each of the SNPs:
For rs35652124, allele A (reference allele) was present in
75.88% of controls and 73.20% of patients, and allele G was
present in 24.12% of controls and 26.80% of patients
(OR= 1.15 [CI 0.93–1.42], p= 0.191). For rs6706649, allele G
(reference allele) was present in 87.57% of controls and
89.97% of patients, and allele A was present in 12.43% of
controls and 13.03% of patients (OR= 1.06 [CI 0.80–1.39],
p= 0.700). Finally, for rs6721961, allele C (reference allele)
was present in 90.54% of controls and 88.71% of patients, and
allele A was present in 9.46% of controls and 11.29% of pa-
tients (OR= 1.22 [CI 0.91–1.64], p= 0.192). Finally, when
NFE2L2 haplotypes were constructed for patients and con-
trols, four haplotypes with frequencies >1% were identified
(Table 2). There was no difference in the frequency of each of
these haplotypes between patients and controls (all p> 0.05;
Table 2). However, each of these haplotypes was marked by
only one NFE2L2 promoter SNP minor allele (Table 2);
hence, these results are not more informative than the
aforementioned individual analyses (Table 1). In summary,
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these results indicate that neither the individual NFE2L2
promoter SNPs nor the main respective NFE2L2 promoter
haplotypes are independent risk factors for HT.
Combined NFE2L2 promoter genotypes and HT risk
The three functional NFE2L2 SNPs lie close together within
36 bp of the promoter, and reporter gene assays have shown that
promoter activity decreases with a higher number of minor
alleles (27). Therefore, we next considered the joint impact of
all three NFE2L2 SNPs on HT risk. Heterozygosity or homo-
zygosity for any 1, 2, or 3 of theNFE2L2SNP minor alleles was
not significantly associated with increased HT risk ( p= 0.072;
Table 3). Nevertheless, the fact that the p-value was close to
significance prompted us to investigate the possible interaction
of theNFE2L2SNPs with the SELENOS functional SNP known
to impact the risk of HT in the same population (10).
Interactions between individual NFE2L2 and SELENOS
promoter SNP genotypes and HT risk
Next, for each of the NFE2L2 SNPs, its effect was assessed
in combination with the previously documented SELENOS
SNP risk allele (10). These analyses included 586 subjects
successfully genotyped for all three NFE2L2 SNPs and for
the SELENOS SNP (322 patients and 264 controls). First,
each NFE2L2 SNP was considered separately. In subjects not
carrying the known SELENOS risk allele (GG homozygotes),
heterozygosity or homozygosity for an NFE2L2 SNP minor
allele did not modify the risk of HT (all p > 0.05; Tables 4–6,
group 2 vs. group 1). Similarly, in subjects heterozygous or
homozygous for the SELENOS risk allele (GA or AA, re-
spectively), heterozygosity or homozygosity for an NFE2L2
SNP minor allele did not modify the risk of HT (all p> 0.05;
Tables 4–6, group 4 vs. group 3). Finally, homozygosity for
an NFE2L2 SNP major allele did not abolish the increased
HT risk associated with heterozygosity or homozygosity for
the SELENOS risk allele (all p > 0.05; Tables 4–6, group 3
vs. group 1). In summary, these results indicate that when
each of the three functional NFE2L2 promoter SNPs is
considered individually, none of them either increases or
abolishes the risk of HT associated with the SELENOS
promoter functional SNP.
Interactions between combined NFE2L2 and SELENOS
promoter SNP genotypes and HT risk
Finally, we considered the combined impact of all three
NFE2L2 SNPs on the risk of HT associated with the SELENOS
promoter functional SNP genotype. In subjects not carrying
the known SELENOS risk allele, heterozygosity or homozy-
gosity for any one of the NFE2L2 SNP minor alleles did not
modify the risk of HT ( p= 0.979; Table 7, group 2 vs. group
1). Moreover, the presence of additional NFE2L2 SNP minor
alleles (from 2 to 6 total) also did not modify the risk of HT
compared with the presence of a single minor allele ( p= 0.879;
Table 7, group 3 vs. group 2). These results are consistent with
the notion that the NFE2L2 promoter genotype is not an in-
dependent risk factor for HT (Tables 1–3). However, among
subjects harboring only major NFE2L2 alleles, heterozygosity
or homozygosity for the SELENOS SNP minor allele was not
associated with increased risk of HT ( p= 0.704; Table 7, group
3 vs. group 1), suggesting a protective effect of the NFE2L2
major alleles. In further support of an interaction effect, in
Table 1. Frequencies of Individual NFE2L2 Promoter Single-Nucleotide Polymorphism Genotypes in
Hashimoto’s Thyroiditis (HT) Patients and Controls, and Calculated Risk of HT for Each Genotype
NFE2L2 SNP Genotype Controls, n (%) Patients, n (%) OR [CI] p*
rs35652124 AA 299 (58.2) 218 (54.1) 1a N/A
AG 182 (35.4) 154 (38.2) 1.11 [0.84–1.48] 0.469
GG 33 (6.4) 31 (7.7) 1.24 [0.73–2.12] 0.436
AG or GG 215 (41.8) 185 (45.9) 1.13 [0.86–1.49] 0.365
rs6706649 GG 413 (76.1) 299 (74.2) 1a N/A
GA 125 (23.0) 103 (25.6) 1.13 [0.83–1.54] 0.444
AA 5 (0.9) 1 (0.2) 0.29 [0.03–2.57] 0.267
GA or AA 130 (23.9) 104 (25.8) 1.10 [0.81–1.50] 0.528
rs6721961 CC 453 (81.6) 319 (79.2) 1a N/A
CA 99 (17.8) 77 (19.1) 1.16 [0.83–1.63] 0.392
AA 3 (0.5) 7 (1.7) 2.34 [0.58–9.42] 0.233
CA or AA 102 (18.4) 84 (20.8) 1.21 [0.87–1.68] 0.269
Model adjusted for sex and age.
*Versus respective reference group.
aReference groups.
CI, confidence interval; N/A, not applicable; OR, odds ratio; SNP, single-nucleotide polymorphism.
Table 2. NFE2L2 Promoter Haplotypes
and Respective Calculated Risk
of Hashimoto’s Thyroiditis
NFE2L2
haplotype
SNP
genotypesa Frequency OR [CI] p
1b A G C 0.516 1 N/A
2 A A C 0.128 1.13 [0.83–1.54] 0.425
3 A G A 0.102 1.31 [0.95–1.81] 0.098
4 G G C 0.254 1.17 [0.93–1.47] 0.182
Minor alleles are underlined. Model adjusted for sex and age.
aBy order of position on chromosome 2: rs35652124, rs6706649,
and rs6721961.
bReference haplotype.
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Table 3. Number of Combined NFE2L2 Promoter Single-Nucleotide Polymorphism Minor Alleles
and Respective Calculated Risk of Hashimoto’s Thyroiditis
Group
NFE2L2
minor alleles, n
Controls,
n (%)
Patients,
n (%) OR [CI]
Vs.
group p
1 0 78 (29.6) 72 (22.4) 1 N/A N/A
2 1–6a 186 (70.4) 250 (77.6) 1.43 [0.97–2.10] 1 0.072
Model adjusted for sex and age.
aMinor allele heterozygous or homozygous for any NFE2L2 promoter SNPs.
Table 4. Frequencies of the SELENOS rs28665122 and NFE2L2 rs35652124 Single-Nucleotide
Polymorphism Combined Genotypes in HT Patients and Controls,
and Calculated Risk of HT for Each Genotype
Group
SELENOS
rs28665122
genotype
NFE2L2
rs35652124
genotype
SELENOS
minor
alleles, n
NFE2L2
minor
alleles, n
Controls,
n (%)
Patients,
n (%) OR [CI]
Vs.
group p
1 GG AA 0 0 115 (43.6) 100 (31.1) 1.00 N/A N/A
2 GG AG or GG 0 1–2 71 (26.9) 65 (20.2) 0.97 [0.62–1.52] 1 0.893
3 GA or AA AA 1–2 0 42 (15.9) 80 (24.8) 2.09 [1.30–3.37] 1 0.002
4 GA or AA AG or GG 1–2 1–2 36 (13.6) 77 (23.9) 1.15 [0.66–2.02] 3 0.621
Bold indicates statistical significance.
Model adjusted for sex and age.
Table 5. Frequencies of the SELENOS rs28665122 and NFE2L2 rs6706649 Single-Nucleotide
Polymorphism Combined Genotypes in HT Patients and Controls,
and Calculated Risk of HT for Each Genotype
Group
SELENOS
rs28665122
genotype
NFE2L2
rs6706649
genotype
SELENOS
minor
alleles, n
NFE2L2
minor
alleles, n
Controls,
n (%)
Patients,
n (%) OR [CI]
Vs.
group p
1 GG GG 0 0 131 (49.6) 125 (38.8) 1.00 N/A N/A
2 GG GA or AA 0 1–2 55 (20.8) 40 (12.4) 0.82 [0.50–1.34] 1 0.425
3 GA or AA GG 1–2 0 64 (24.2) 114 (35.4) 1.93 [1.28–2.91] 1 0.002
4 GA or AA GA or AA 1–2 1–2 14 (5.3) 43 (13.3) 1.62 [0.81–3.24] 3 0.174
Bold indicates statistical significance.
Model adjusted for sex and age.
Table 6. Frequencies of the SELENOS rs28665122 and NFE2L2 rs6721961 Single-Nucleotide
Polymorphism Combined Genotypes in HT Patients and Controls,
and Calculated Risk of HT for Each Genotype
Group
SELENOS
rs28665122
genotype
NFE2L2
rs6721961
genotype
SELENOS
minor
alleles, n
NFE2L2
minor
alleles, n
Controls,
n (%)
Patients,
n (%) OR [CI]
Vs.
group p
1 GG CC 0 0 152 (57.6) 133 (41.3) 1.00 N/A N/A
2 GG CA or AA 0 1–2 34 (12.9) 32 (9.9) 1.07 [0.61–1.88] 1 0.806
3 GA or AA CC 1–2 0 63 (23.8) 122 (37.9) 2.20 [1.48–3.28] 1 <0.001
4 GA or AA CA or AA 1–2 1–2 15 (5.7) 35 (10.9) 1.24 [0.62–2.50] 3 0.546
Bold indicates statistical significance.
Model adjusted for sex and age.
Table 7. Interaction Between Number of Combined NFE2L2 Promoter Single-Nucleotide Polymorphism
Minor Alleles and SELENOS Minor Alleles, and Respective Calculated Risk of HT
Group
SELENOS
minor alleles, n
NFE2L2
minor alleles, n
Controls,
n (%)
Patients,
n (%) OR [CI] Vs. group p
1 0 0 49 (18.6) 42 (13.0) 1 N/A N/A
2 0 1 99 (37.5) 90 (30.0) 1.01 [0.60–1.69] 1 0.979
3 0 2–6a 38 (14.4) 33 (10.2) 0.95 [0.53–1.71] 2 0.879
4 1–2 0 29 (11.0) 30 (9.3) 1.14 [0.58–2.24] 1 0.704
5 1–2 1 31 (11.7) 86 (26.7) 2.84 [1.44–5.58] 4 0.003
6 1–2 2–6a 18 (6.8) 41 (12.7 0.75 [0.37–1.53] 5 0.428
Bold indicates statistical significance.
Model adjusted for sex and age.
aMinor allele heterozygous or homozygous for any NFE2L2 promoter SNPs.
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subjects heterozygous or homozygous for the SELENOS risk
allele, heterozygosity or homozygosity for any one of the
NFE2L2 SNP minor alleles significantly increased the risk of
HT by 2.8-fold ( p= 0.003; Table 7, group 5 vs. group 4),
suggesting a predisposing effect of the NFE2L2 minor alleles.
Of note, statistical significance was retained after controlling
for the effects of multiple testing using the FDR method.
Subjects with additional NFE2L2 SNP minor alleles (from 2
to 6 total) had the same level of risk of HT as those with a
single minor allele ( p = 0.428; Table 7, group 6 vs. group 5).
In summary, these results indicate that when the three
NFE2L2 promoter functional SNPs are considered together
and in combination with the SELENOS promoter functional
SNP, NFE2L2 major alleles abolish the HT risk associated
with the SELENOS minor allele, whereas NFE2L2 minor
alleles increase the risk.
Reduced expression of SelS in thyroid follicular
cells of Hashimoto’s patients
To better understand how the genetic interaction between
SELENOS and NFE2L2 may impact the susceptibility to
Hashimoto’s disease, we first analyzed the expression of
SelS protein by immunohistochemistry in thyroid samples
from control subjects (n = 10) or patients with HT (n = 8),
collected during thyroidectomy performed for other indications
(notably benign goiter). Representative immunohistochemi-
cal stainings and respective staining intensity scores are
shown in Figure 1A, and the distribution of staining inten-
sities among samples is depicted in the histograms shown in
Figure 1B. There was a statistically significant lower ex-
pression of SelS ( p £ 0.001) in the thyroid follicular cells of
HT compared with those in control samples. Interestingly,
despite the reduced expression of SelS in thyroid follicular
cells in Hashimoto’s samples, a subset of lymphocytes in
germinal centers and other lymphocytic infiltrates stained
strongly for SelS.
Reduced expression of SelS in thyroid follicular
cells of Nrf2-KO mice
We next analyzed by RT-PCR, Western immunoblotting,
and immunohistochemistry the expression of SelS mRNA
and SelS protein, respectively, in thyroid samples from WT
and Nrf2-KO mice. No difference was found at the SelS
mRNA level between the genotypes (Fig. 2A) in thyroid
tissue. However, thyroidal SelS protein levels were significantly
reduced in Nrf2-KO mice (Fig. 1C, E). Immunohistochemistry
showed that this reduction was associated with reduced
expression in the thyroid follicular cells (Fig. 1G). When
liver tissue samples were analyzed, no differences were
observed in either SelS mRNA (Fig. 1B) or SelS protein
levels (Fig. 1D, F), suggesting that the observed differences
in thyroid are a tissue-specific effect.
FIG. 1. Expression of SelS
in samples from control sub-
jects and Hashimoto’s pa-
tients. (A) Representative
immunohistochemical stain-
ings and respective staining
intensity scores. The H&E
panels and the upper SelS
panels are taken at · 100
magnification; the magnified
inserts are taken at · 300
magnification. Arrows indi-
cate stained areas represen-
tative of the respective
overall scores. Stars indicate
germinal centers and other
lymphocytic infiltrates, in
which a subset of lympho-
cytes stains strongly for SelS.
(B) Quantification of SelS
staining intensity in thyroid
follicular cells in samples
from control subjects and
Hashimoto’s patients. H&E,
hematoxylin and eosin; SelS,
selenoprotein S.
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SELENOS is not a transcriptional target gene of Nrf2
To further investigate how Nrf2 impacts SelS levels, we
examined whether it may positively regulate the activity
of the human SELENOS promoter. To that end, we cloned
three fragments of the SELENOS promoter into luciferase
reporter constructs to perform activity assays in tran-
siently transfected PCCL3 rat thyroid follicular cells. All
fragments contain a known ER stress-responsive element
(52), and the two longer fragments also contain, respec-
tively, one or two predicted ARE sites (Fig. 3A). In both
PCCL3 WT and Nrf2-KO cells, all reporter constructs
showed significant inducibility by the ER stress-inducing
compound TN, but no inducibility in response to treatment
with the Nrf2 inducer SLF (Fig. 3B, C). In the same cells, TN,
but not SLF, significantly induced the SelS mRNA and SelS
protein levels (Fig. 1D, E). Genetic activation of Nrf2 (as
observed in Keap1-KO PCCL3 cells (38)) also had no effect
on basal or inducible SelS mRNA and SelS protein levels
(Fig. 1D, E). Taken together, these data indicate that Nrf2
does not have a direct effect on the SELENOS promoter but
that it positively regulates SelS protein levels in thyroid fol-
licular cells in a posttranscriptional manner.
Reduced activity of Nrf2 signaling in thyroid follicular
cells with reduced SelS expression
We also aimed to investigate the effects of SelS on Nrf2
signaling. To that end, we first established conditions for an
efficient knockdown of SelS in PCCL3 cells, by combining
three siRNA constructs yielding a strong additive effect
(Fig. 3A, B). SelS knockdown decreased the mRNA ex-
pression levels of Nqo1, the prototypical Nrf2 target gene,
both under basal conditions and in response to pharmaco-
logical induction of Nrf2 by SLF or genetic activation of Nrf2
(Keap1-KO) (Fig. 4C). The thyroidal mRNA levels of Gpx2
and Txnrd1 have also been previously shown to be regulated,
in part, by Nrf2 (38); SelS knockdown decreased their mRNA
expression levels under basal conditions and in response to
genetic activation of Nrf2 (Keap1-KO), but not in response to
pharmacological induction of Nrf2 by SLF (Fig. 4D–E), which
may be because the latter compound can also modulate other
FIG. 2. Expression of SelS
mRNA and SelS protein in WT and
Nrf2-KO mice. (A, B) Relative
SelS mRNA expression levels,
quantified by RT-PCR and nor-
malized to PPIA as the reference
gene, in the thyroid (A) or liver
(B) of WT and Nrf2-KO male mice
under basal conditions. Error bars
indicate mean – standard deviation.
(C, D) SelS protein levels assayed
by Western immunoblotting in
protein extracts from thyroid (C) or
liver (D) of WT and Nrf2- KO
male mice (7 mice per group).
(E, F) Densitometric quantification
of relative protein levels in the
mice shown in (C, D), respectively,
was performed using ImageJ, with
normalization to the respective
actin levels and to the mean value
of the WT group. Error bars
indicate mean – standard deviation.
*p < 0.05. (G) Representative im-
munohistochemical stainings and
respective staining intensity scores
of SelS expression in thyroid fol-
licular cells in samples from WT
and Nrf2-KO mice (all taken
at · 400 magnification). KO,
knockout; mRNA, messenger
RNA; RT-PCR, real-time poly-
merase chain reaction; WT, wild
type.
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signaling pathways and biological processes (53). Finally, we
examined the effects of SelS and Nrf2 on cell viability under
conditions of ER stress or oxidative stress. Cell viability was
not reduced by treatment with either TN or SLF (Fig. 4F).
However, knockdown of SelS reduced cell viability specifi-
cally in response to TN treatment, and pretreatment of the cells
with SLF was unable to rescue this effect. Conversely, when
cells were exposed to oxidative stress generated by treatment
with menadione, cells were almost completely unviable, yet
SLF pretreatment was able to fully rescue this toxicity. How-
ever, when SelS was knocked down, the ability of SLF pre-
treatment to rescue the viability of cells was significantly
reduced. Taken together, these data indicate that SelS posi-
tively impacts the activity of Nrf2 signaling and its down-
stream protective effects against oxidative stress-induced cell
toxicity.
Discussion
The present study expands the known roles of Nrf2 in the
thyroid to include protection from autoimmune thyroid
disease. The data indicate that NFE2L2 SNPs do not act in
isolation from other genes, but that they interact as a group
specifically with the SNP in SELENOS that has been pre-
viously associated with HT (10). This is indicated by the
results shown in Table 7, which demonstrate not only that
NFE2L2 minor alleles confer a risk when present together
with the SELENOS minor allele but also that the presence of
only NFE2L2 major alleles abolishes the HT risk associated
with the SELENOS minor allele. These data are consistent
with the signaling interactions between the Nrf2 and SelS
systems in thyroid cells described in Figures 2–4, which
suggest that there is a certain level of physiological
FIG. 3. Functional assessment of potential Nrf2-binding sites in the human SELENOS promoter. (A) Schematic repre-
sentation of the human SELENOS promoter constructs, indicating the location of the two putative ARE sequences and of a
previously characterized ESRE, as well as the length of each promoter sequence cloned in a respective luciferase reporter
plasmid (P1, P2, P3). (B, C) Activity of the each SELENOS promoter reporter construct in WT (B) or Nrf2-KO (C) PCCL3
cells treated with vehicle (<0.1% DMSO), TN, or SLF and lysed 24 hours later to measure luciferase activity. Results are
presented as fold change over the normalized activity of the P1 construct in WT (B) and Nrf2-KO cells (C), respectively.
Error bars indicate mean – standard deviation of at least three independent experiments. *p < 0.05 versus respective vehicle-
treated control. (D, E) Impact of Nrf2 activation status on the inducibility of SelS mRNA and SelS protein expression by ER
stress. PCCL3 WT or Nrf2-KO or Keap1-KO cells cultured in complete medium and treated with 0.5 lg/mL of TN or 5lM
of SLF or vehicle (<0.1% DMSO) were lysed 24 hours later. (D) Relative mRNA levels of SelS normalized to Rpl19 as the
reference gene were quantified by RT-PCR. Error bars indicate mean – standard deviation of at least three independent
experiments. *p< 0.05 versus the vehicle-treated control in WT cells. (E) Representative Western blot of one of the
experiments illustrated in (D), showing SelS protein levels with vinculin as a loading control. DMSO, dimethylsulfoxide;
ER, endoplasmic reticulum; ESRE, ER stress-responsive element; SLF, sulforaphane; TN, tunicamycin.
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FIG. 4. Impact of SelS gene silencing on Nrf2 target gene expression and viability after ER or oxidative stress challenge.
(A, B) Validation of siRNA-mediated silencing of SelS. PCCL3 cells were transfected with individual siRNAs (si_1, si_2, or
si_3, all at a final concentration of 20 nM) or all three siRNAs combined (si_123, each at a final concentration of 6.6 nM); a
nontargeting siRNA (si_C) was used in parallel as negative control. Cells were lysed 48 hours after transfection. (A)
Relative SelS mRNA expression levels were determined by RT-PCR and normalized to Rpl19. Error bars indicate
mean – standard deviation of at least three independent experiments. *p < 0.05 versus si_C. (B) Representative Western
immunoblotting showing SelS protein knockdown with vinculin as a loading control. (C–E). Effect of SelS silencing on
Nrf2 target genes. PCCL3 WT or Keap1-KO cells transfected with a pool of three siRNAs (_si) or with a negative control
siRNA (_C), as described above, were treated 24 hours later as indicated with vehicle (<0.1% DMSO) or 5 lM SLF for
24 hours. Relative mRNA expression levels of Nqo1 (C), Gpx2 (D), and Txnrd1 (E) were determined by RT-PCR and
normalized to Rpl19. Error bars indicate mean – standard deviation of at least three independent experiments. *p < 0.05
versus the levels in respective cells treated with negative control siRNA (_C). (F) Effects of SelS silencing on cell viability
under ER stress or oxidative stress conditions. WT PCCL3 cells were transfected in 6-well plates with a pool of three
siRNAs (si) or with a negative control siRNA (C), as described above; 12 hours later, cells were trypsinized and equal
numbers of cells were plated in 96-well plates. After 24 hours, cells were treated with vehicle (<0.1% DMSO), 5 lM SLF, or
0.5 lg/mL TN, as indicated, for another 24 hours; 20 nM MN were added during the last 8 hours of this period. The viability
of the cells was then assessed (60 hours after transfection) by an adenosine triphosphate-based luminescence assay as
detailed in the Materials and Methods section, and normalized to the viability of untreated cells. Error bars indicate
mean – standard deviation of at least three independent experiments. *p< 0.05 versus the levels in respective cells as
indicated in each case; #p< 0.05 versus the levels in control untreated cells (set at ‘‘1’’); $p < 0.05 versus the levels in
si_SLF_MN cells. MN, menadione; ns, nonsignificant; siRNA, small interfering RNA.
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compensation and bidirectional positive feedback between
the two pathways.
Previous studies have implicated Nrf2 in papillary thyroid
carcinoma (44), goiter (54,55), antioxidant defense in re-
sponse to excess iodide (38,56), and Tg economy (38). While
the mechanism through which the NFE2L2 minor alleles
contribute to the risk of HT remains to be characterized, some
plausible hypotheses can already be proposed. Using Nrf2 KO
mice and thyrocyte cell lines, we have recently shown that
Nrf2 mediates antioxidant transcriptional responses in thy-
roid follicular cells and protects the thyroid from oxidation
induced by iodide overload (38). In that work, we also found
that Nrf2 has a dramatic impact on both the basal abundance
and the TSH-inducible intrathyroidal abundance of Tg, an
effect mediated by cell autonomous regulation of TG gene
expression by Nrf2 via its direct binding to two evolutionarily
conserved AREs in an upstream enhancer (38). Yet, despite
upregulating Tg levels, Nrf2 was found to limit Tg iodination
both under basal conditions and in response to excess iodide
(38). Thus, it is possible that when Nrf2 levels are reduced due
to the presence of NFE2L2 minor alleles, Tg iodination is
increased. Because increased and aberrant Tg iodination can
uncover cryptic antigenic epitopes (57), an increase in Tg
iodination associated with NFE2L2 minor alleles might, over
the long term, contribute to the pathogenesis of HT. Another
possibility concerns the general antiautoimmunity role of
Nrf2; this has been demonstrated in studies in Nrf2 KO mice.
When these mice are bred into autoimmunity-permissive
genetic backgrounds, a subset of them develops a multiorgan
autoimmune syndrome (35–37). These studies indicate that
Nrf2 has a protective role against autoimmunity, either via
actions in each individual tissue (as Nrf2 is ubiquitously ex-
pressed) or via actions in the immune system that impact self-
tolerance toward various autoantigens. Of course, the two
aforementioned hypotheses (increased Tg iodination and
deregulated autoimmunity) are not mutually exclusive.
The present study also expands the known interactions be-
tween Nrf2 and the selenium system. Selenium and Nrf2 reg-
ulate similar proteostatic processes, including antioxidant
defense and the ER stress response; for example, both SelS and
Nrf2 function as mediators of ERAD (11,58). Moreover, sele-
nium and Nrf2 regulate proteostasis not only independently but
also via converging on common genes and proteins. For ex-
ample, Nrf2 directly upregulates the transcription of genes
encoding selenoproteins, including Gpx2 and Txnrd1 (38),
which are both known to participate in redox signaling and
antioxidant defense, as well as to have important homeostatic
roles in thyroid follicular cells (39,40). In this context, it is not
surprising that multiple lines of evidence indicate that the se-
lenoprotein system and the Nrf2 system can compensate for
each other in antioxidant stress responses (18,19). For example,
moderate selenium deficiency activates Nrf2 signaling in the
liver and intestine of mice (20,21). Tissue-specific deletion of
the selenocysteine tRNA gene, which inserts selenocysteine
into selenoprotein enzymes, results in compensatory induction
by Nrf2 of genes encoding cytoprotective enzymes (22). Thus,
in these settings, the simultaneous disruption of the two systems
is particularly deleterious to proteostasis, leading to enhanced
disease phenotypes (22,23). These types of interactions have
been documented in animal studies focusing on different tis-
sues, including erythrocyte precursors, macrophages, and liver
(22,23). Our present findings using human genetics and com-
plementary human-, animal-, and cell-based studies indicate
that such an interaction is also at play in the thyroid gland,
which makes sense given that both selenium and oxidation are
central elements in thyroid physiology.
The genetic and signaling interactions between the Nrf2
and Sels pathways and their impact on susceptibility or re-
sistance to HT are summarized in the model proposed in
Figure 5. Nrf2 and SelS are known to favor resistance to
oxidative stress and ER stress, respectively; moreover, both
Nrf2 and SelS are also both known to suppress the expression
of proinflammatory cytokines, including IL-6 and IL-1b,
which are two cytokines known to be involved in the path-
ogenesis of HT (12,59). In addition to general interactions
between the Nrf2 and SelS protective systems, thyroid-specific
mechanisms may also exist. For example, one explanation for
the lower levels of SelS in the thyroid of Nrf2-KO mice may be
the fact that these mice have lower levels of Tg (38). Since Tg
comprises the bulk of the thyroid’s protein content and rep-
resents a high-molecular-weight protein that depends critically
on the ER for its proper conformation, the lower Tg levels in
Nrf2-KO mice may impose a lower burden on the ER. Pre-
vious studies have shown that SelS is positively regulated by
ER stress (52), suggesting that lower ER stress levels in Nrf2-
KO mice (and, potentially, in carriers of NFE2L2 minor SNP
alleles) may lead to decreased SelS expression. Conversely,
FIG. 5. Proposed model of genetic and signaling interactions
between the Nrf2 and SelS pathways and their impact on sus-
ceptibility or resistance to HT. The model illustrates the ex-
pected situation in an individual who is homozygous for the
major alleles of the three functional SNPs in NFE2L2
(rs35652124,-214A>G; rs6706649,-212G>A; and rs6721961,
-178A>C) and also homozygous for the major allele of the
functional SNP in SELENOS (rs28665122, -105G/A). In this
setting, the Nrf2 and SelS pathways protect against the devel-
opment of HT, possibly by suppressing the expression of in-
flammatory cytokines and promoting resistance to oxidative
and ER stress. The present study also provides evidence of a
bidirectional positive feedback between the Nrf2 and SelS
pathways. Specifically, Nrf2 positively regulates SelS protein
levels in thyroid follicular cells in a posttranscriptional manner.
Conversely, SelS positively impacts the activity of Nrf2 sig-
naling and its downstream protective effects against oxidative
stress-induced cell toxicity. HT, Hashimoto’s thyroiditis.
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our findings show that SelS has a positive effect on the activity
of Nrf2 signaling, because reduction of SelS levels causes a
reduction in the mRNA expression levels of Nrf2 target genes.
Interestingly, this effect is also observed in Keap1-KO cells,
suggesting that the underlying mechanism is Keap1 indepen-
dent and thus likely involves a downstream step in Nrf2 sig-
naling. In summary, the presence of a bidirectional positive
feedback between the SelS and Nrf2 systems may explain why
even small variations in gene expression (as a result of the
SNPs) and/or activity of either pathway may be amplified,
leading to phenotypic effects. Clearly, the roles of Nrf2 in the
thyroid and its cross talk with other proteostatic systems in this
gland warrant further elucidation.
This study has some limitations. First, it is acknowledged
that a biological interaction between the two pathways is not
an independent proof of a genetic interaction (epistasis).
Second, it is interesting that subjects with additional NFE2L2
SNP minor alleles (from 2 to 6 in total) had the same level of
risk for developing HT as those with a single minor allele.
Even though a simple gene dosage model is easier to con-
ceptualize, for a multifactorial disease of essentially un-
known pathogenesis such as HT, other models, such a
threshold model, are equally plausible. In fact, we speculate
that a signaling interaction between the two genetically in-
teracting pathways might actually better fit a threshold
model. Finally, it is acknowledged that the observed inter-
action may not apply to all ethnicities. A recent genome-wide
association study (GWAS) performed on a Croatian popu-
lation suggested novel loci for HT, but did not find associa-
tions with SELENOS or NFE2L2 variants (60). Of note, that
study did not test specifically for an interaction between
SELENOS and NFE2L2 variants. Also, there were several
factors that differentiate it from the present study, including
the very specific and distinct ethnic origins of the participants
in the two studies (Portuguese vs. Croatian); the different
clinical profiles of HT patients in the two studies (e.g., overt
hypothyroidism in all HT patients in the Portuguese cohort
vs. inclusion of HT patients with subclinical hypothyroidism
or even spontaneous euthyroidism in the Croatian study); and
the relatively small population size (for a GWAS) of the
Croatian cohort (838 participants with usable data in the
discovery cohort) (60). The presence of striking ethnic pat-
terns in HT susceptibility indicating the implication of eth-
nically restricted effects has been well acknowledged (3). It
will thus be interesting to perform replication studies for the
genetic interaction between SELENOS and NFE2L2 variants
in various independent ethnic cohorts of HT patients.
The importance of selenium for the thyroid has long been
known. Selenium supplementation is recommended for the
treatment of orbitopathy associated with autoimmune hy-
perthyroidism (Graves’ disease) (61), and it is also currently
being tested in a randomized controlled clinical trial as a
therapeutic measure for chronic autoimmune thyroiditis (HT)
(62). In view of the present findings, it might be interesting
to test combinations of selenium with Nrf2 activating
compounds, such as SLF-containing natural extracts, whose
safety for the thyroid has actually been shown in a recent
clinical trial (63).
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